IL-27, a pleiotropic cytokine for fine-tuning the immune response in cancer

References

• Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002;16(6):779–790. DOI: 10.1016/s1074-7613(02)00324-2
   PubMed Web of Science ®Google Scholar
• Villarino A, Hibbert L, Lieberman L, et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity. 2003;19(5):645–655. [PMID: 14614852 DOI: 10.1016/s1074-7613(03)00300-5
   PubMed Web of Science ®Google Scholar
• Hunter CA, Kastelein R. Interleukin-27: balancing protective and pathological immunity. Immunity. 2012;37(6):960–969. DOI: 10.1016/j.immuni.2012.11.003
   PubMed Web of Science ®Google Scholar
• Jankowski M, Kopiński P, Goc A. Interleukin-27: biological properties and clinical application. Arch Immunol Ther Exp (Warsz). 2010 Dec;58(6):417–425. DOI:10.1007/s00005-010-0098-6. Epub 2010 Sep 26. PMID: 20872282.
   PubMed Web of Science ®Google Scholar
• Pflanz S, Hibbert L, Mattson J, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004;172(4):2225–2231. DOI: 10.4049/jimmunol.172.4.2225
   PubMed Web of Science ®Google Scholar
• Pradhan A, Lambert QT, Reuther GW. Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor. Proc Natl Acad Sci USA. 2007;104(47):18502–18507. DOI: 10.1073/pnas.0702388104
   PubMed Web of Science ®Google Scholar
• Dai L, Lidie KB, Chen Q, et al. IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. J Exp Med. 2013;210(3):517–534. [PMID: 23460728 DOI: 10.1084/jem.20120572
   PubMed Web of Science ®Google Scholar
• Zwirner NW, Ziblat A. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: the case of IL-27. Front Immunol. 2017;8:25. DOI: 10.3389/fimmu.2017.00025
   PubMed Web of Science ®Google Scholar
• Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol. 2009;27:29–60. DOI: 10.1146/annurev.immunol.24.021605.090616
   PubMed Web of Science ®Google Scholar
• Devergne O, Hummel M, Koeppen H, et al. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol. 1996;70(2):1143–1153. DOI: 10.1128/JVI.70.2.1143-1153.1996.
   PubMed Web of Science ®Google Scholar
• Dagil R, Knudsen MJ, Olsen JG, et al. The WSXWS motif in cytokine receptors is a molecular switch involved in receptor activation: insight from structures of the prolactin receptor. Structure. 2012;20(2):270–282. DOI: 10.1016/j.str.2011.12.010
   PubMed Web of Science ®Google Scholar
• Rousseau F, Basset L, Froger J, Dinguirard N, Chevalier S, Gascan H. IL-27 structural analysis demonstrates similarities with ciliary neurotrophic factor (CNTF) and leads to the identification of antagonistic variants. Proc Natl Acad Sci USA. 2010;107(45):19420–19425. DOI: 10.1073/pnas.1005793107
   PubMed Web of Science ®Google Scholar
• Dietrich C, Candon S, Ruemmele FM, Devergne O. A soluble form of IL-27Rα is a natural IL-27 antagonist. J Immunol. 2014;192(11):5382–5389. DOI: 10.4049/jimmunol.1303435
   PubMed Web of Science ®Google Scholar
• Wang QL. regulation and immune function of IL-27. In: Xiaojing M, ed. Regulation of Cytokine Gene Expression in Immunity and Diseases Advances in Experimental Medicine and Biology. Dordrecht: Springer; 2016.
   Google Scholar
• Swaminathan S, Dai L, Lane HC, Imamichi T. Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection. Cytokine Growth Factor Rev. 2013;24(6):571–577. DOI: 10.1016/j.cytogfr.2013.07.001
   PubMed Web of Science ®Google Scholar
• Shimizu M, Shimamura M, Owaki T, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol. 2006;176(12):7317–7324. DOI: 10.4049/jimmunol.176.12.7317
   PubMed Web of Science ®Google Scholar
• Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J Immunol. 2004;173(2):1171–1178. DOI: 10.4049/jimmunol.173.2.1171
   PubMed Web of Science ®Google Scholar
• Goldberg R, Zohar Y, Wildbaum G, Geron Y, Maor G, Karin N. Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J Immunol. 2004;173(10):6465–6471. DOI: 10.4049/jimmunol.173.10.6465
   PubMed Web of Science ®Google Scholar
• Cox JH, Kljavin NM, Ramamoorthi N, Diehl L, Batten M, Ghilardi N. IL-27 promotes T cell-dependent colitis through multiple mechanisms. J Exp Med. 2011;208(1):115–123. DOI: 10.1084/jem.20100410
   PubMed Web of Science ®Google Scholar
• Kim G, Shinnakasu R, Saris CJM, Cheroutre H, Kronenberg M. A novel role for IL-27 in mediating the survival of activated mouse CD4 T lymphocytes. J Immunol. 2013;190(4):1510–1518. DOI: 10.4049/jimmunol.1201017
   PubMed Web of Science ®Google Scholar
• Mittal A, Murugaiyan G, Beynon V, Hu D, Weiner HL. IL-27 induction of IL-21 from human CD8+ T cells induces granzyme B in an autocrine manner. Immunol Cell Biol. 2012;90(8):831–835. DOI: 10.1038/icb.2012.14
   PubMed Web of Science ®Google Scholar
• Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol. 2011;41(1):47–59. DOI: 10.1002/eji.201040804
   PubMed Web of Science ®Google Scholar
• Matsui M, Kishida T, Nakano H, et al. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 2009;69(6):2523–2530. DOI: 10.1158/0008-5472.CAN-08-2793
   PubMed Web of Science ®Google Scholar
• Batten M, Ramamoorthi N, Kljavin NM, et al. IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells. J Exp Med. 2010;207(13):2895–2906. DOI: 10.1084/jem.20100064
   PubMed Web of Science ®Google Scholar
• Gringhuis SI, Kaptein TM, Wevers BA, et al. Fucose-based PAMPs prime dendritic cells for follicular T helper cell polarization via DC-SIGN-dependent IL-27 production. Nat Commun. 2014;5:5074. DOI: 10.1038/ncomms6074
   PubMed Web of Science ®Google Scholar
• Huber M, Steinwald V, Guralnik A, et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol. 2008;20(2):223–234. DOI: 10.1093/intimm/dxm139
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol. 2008;180(9):6325–6333. DOI: 10.4049/jimmunol.180.9.6325
   PubMed Web of Science ®Google Scholar
• Petes C, Mariani MK, Yang Y, Grandvaux N, Gee K. Interleukin (IL)-6 Inhibits IL-27- and IL-30-mediated inflammatory responses in human monocytes. Front Immunol. 2018;9:256. DOI: 10.3389/fimmu.2018.00256
   PubMed Web of Science ®Google Scholar
• Villarino AV, Stumhofer JS, Saris CJ, Kastelein RA, de Sauvage FJ, Hunter CA. IL-27 limits IL-2 production during Th1 differentiation. J Immunol. 2006;176(1):237–247. DOI: 10.4049/jimmunol.176.1.237.
   PubMed Web of Science ®Google Scholar
• Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol. 2008;180(5):2752–2756. DOI: 10.4049/jimmunol.180.5.2752
   PubMed Web of Science ®Google Scholar
• Owaki T, Asakawa M, Kamiya S, et al. IL-27 suppresses CD28-mediated [correction of medicated] IL-2 production through suppressor of cytokine signaling 3. J Immunol. 2006;176(5):2773–2780. DOI: 10.4049/jimmunol.176.5.2773
   PubMed Web of Science ®Google Scholar
• Guzzo C, Mat NFC, Gee K. Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. J Biol Chem. 2010;285(32):24404–24411. doi:10.1074/jbc.M110.112599.
   PubMed Web of Science ®Google Scholar
• Artis D, Villarino A, Silverman M, et al. The IL-27 receptor (WSX-1) is an inhibitor of innate and adaptive elements of type 2 immunity. J Immunol. 2004;173(9):5626–5634. DOI: 10.4049/jimmunol.173.9.5626
   PubMed Web of Science ®Google Scholar
• Duan M, Ning Z, Fu Z, et al. Decreased IL-27 negatively correlated with Th17 cells in non-small-cell lung cancer patients. Mediators Inflamm. 2015;2015:802939. DOI: 10.1155/2015/802939
   PubMed Web of Science ®Google Scholar
• Stumhofer JS, Laurence A, Wilson EH, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7(9):937–945. DOI: 10.1038/ni1376
   PubMed Web of Science ®Google Scholar
• Yang J, Yang M, Htut TM, et al. Epstein-Barr virus-induced gene 3 negatively regulates IL-17, IL-22 and RORgamma t. Eur J Immunol. 2008;38(5):1204–1214. DOI: 10.1002/eji.200838145
   PubMed Web of Science ®Google Scholar
• Young A, Linehan E, Hams E, et al. Cutting edge: suppression of GM-CSF expression in murine and human T cells by IL-27. J Immunol. 2012;189(5):2079–2083. DOI: 10.4049/jimmunol.1200131
   PubMed Web of Science ®Google Scholar
• Zhang GL, Xie DY, Ye YN, et al. High level of IL‐27 positively correlated with Th17 cells may indicate liver injury in patients infected with HBV. Liver Int. 2014;34(2):266–273. DOI: 10.1111/liv.12268
   PubMed Web of Science ®Google Scholar
• Peters A, Fowler KD, Chalmin F, Merkler D, Kuchroo VK, Pot C. IL-27 induces Th17 differentiation in the absence of STAT1 signaling. J Immunol. 2015;195(9):4144–4153. DOI: 10.4049/jimmunol.1302246
   PubMed Web of Science ®Google Scholar
• Do J, Kim D, Kim S, et al. Treg-specific IL-27Rα deletion uncovers a key role for IL-27 in Treg function to control autoimmunity. Proc Natl Acad Sci USA. 2017;114(38):10190–10195. DOI: 10.1073/pnas.1703100114
   PubMed Web of Science ®Google Scholar
• Horlad H, Ma C, Yano H, et al. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci. 2016;107(11):1696–1704. DOI: 10.1111/cas.13065
   PubMed Web of Science ®Google Scholar
• Hall AOH, Beiting DP, Tato C, et al. The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity. 2012;37(3):511–523. DOI: 10.1016/j.immuni.2012.06.014
   PubMed Web of Science ®Google Scholar
• Moon S-J, Park J-S, Heo Y-J, et al. In vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis. Exp Mol Med. 2013;45(10):e46. DOI: 10.1038/emm.2013.89
   PubMedGoogle Scholar
• Mascanfroni ID, Yeste A, Vieira SM, et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol. 2013;14(10):1054–1063. DOI: 10.1038/ni.2695
   PubMed Web of Science ®Google Scholar
• Kouchaki E, Kakhaki RD, Tamtaji OR, Dadgostar E, et al. Increased serum levels of TNF-α and decreased serum levels of IL-27 in patients with Parkinson disease and their correlation with disease severity. Clinical Neurology and Neurosurgery. 2018;166:76–79. DOI: 10.1016/j.clineuro.2018.01.022.
   PubMed Web of Science ®Google Scholar
• Jin W, Zhao Y, Yan W, et al. Elevated circulating interleukin-27 in patients with coronary artery disease is associated with dendritic cells, oxidized low-density lipoprotein, and severity of coronary artery stenosis. Mediators Inflammation. 2012;2012:506283–506283. DOI: 10.1155/2012/506283
   PubMed Web of Science ®Google Scholar
• Cao J, Xu F, Lin S, et al. IL-27 controls sepsis-induced impairment of lung antibacterial host defence. Thorax. 2014;69(10):926–937. DOI: 10.1136/thoraxjnl-2014-205777
   PubMed Web of Science ®Google Scholar
• Erdmann H, Behrends J, Ritter K, et al. The increased protection and pathology in Mycobacterium tuberculosis-infected IL-27R-alpha-deficient mice is supported by IL-17A and is associated with the IL-17A-induced expansion of multifunctional T cells. Mucosal Immunol. 2018;11(4):1168–1180. DOI: 10.1038/s41385-018-0026-3
   PubMed Web of Science ®Google Scholar
• Abdalla AE, Li Q, Xie L, Xie J. Biology of IL-27 and its role in the host immunity against Mycobacterium tuberculosis. Int J Biol Sci. 2015;11(2):168–175. DOI: 10.7150/ijbs.10464
   PubMed Web of Science ®Google Scholar
• Zheng Y-H, Xiao S-L, He B, He Y, Zhou H-Y, Chen Z, Zheng L-W, He M, Wang H-Y, Lin Y-H, Cao J. The Role of IL-27 and its Receptor in the Pathogenesis of HIV/AIDS and Anti-viral Immune Response. Curr HIV Res. 2017;15(4):279–284. DOI:10.2174/1570162X15666170517130339.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Hu X, Zheng X, et al. Interleukin-27 treated human macrophages induce the expression of novel microRNAs which may mediate anti-viral properties. Biochem Biophys Res Commun. 2013;434(2):228–234. DOI: 10.1016/j.bbrc.2013.03.046
   PubMed Web of Science ®Google Scholar
• Lai X, Wang H, Cao J, et al. Circulating IL-27 Is elevated in rheumatoid arthritis patients. Molecules. 2016;21(11):1565. DOI: 10.3390/molecules21111565
   Web of Science ®Google Scholar
• Rajaiah R, Puttabyatappa M, Polumuri SK, Moudgil KD. Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis. J Biol Chem. 2011;286(4):2817–2825. DOI: 10.1074/jbc.M110.187013
   PubMed Web of Science ®Google Scholar
• Jones GW, Bombardieri M, Greenhill CJ, et al. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. J Exp Med. 2015;212(11):1793–1802. DOI: 10.1084/jem.20132307
   PubMed Web of Science ®Google Scholar
• Qiu F, Song L, Yang N, Li X. Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus. 2013;22(10):1011–1016. DOI: 10.1177/0961203313498799
   PubMed Web of Science ®Google Scholar
• Xia LP, Li BF, Shen H, Lu J. Interleukin-27 and interleukin-23 in patients with systemic lupus erythematosus: possible role in lupus nephritis. Scand J Rheumatol. 2015;44(3):200–205. DOI: 10.3109/03009742.2014.962080
   PubMed Web of Science ®Google Scholar
• Kwan BC-H, Tam L-S, Lai K-B, et al. The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2009;48(12):1491–1497. DOI: 10.1093/rheumatology/kep255
   PubMed Web of Science ®Google Scholar
• Hanson ML, Hixon JA, Li W, et al. Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology. 2014;146(1):210–221. e213. DOI: 10.1053/j.gastro.2013.09.060
   PubMed Web of Science ®Google Scholar
• Sénécal V, Deblois G, Beauseigle D, et al. Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses. Glia. 2016;64(4):553–569. DOI: 10.1002/glia.22948
   PubMed Web of Science ®Google Scholar
• Naderi S, Hejazi Z, Shajarian M, Alsahebfosoul F, Etemadifar M, Sedaghat N. IL-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine. J Immunoassay Immunochem. 2016;37(6):659–670. DOI: 10.1080/15321819.2016.1195746
   PubMedGoogle Scholar
• Kourko O, Seaver K, Odoardi N, Basta S, Gee K. IL-27, IL-30, and IL-35: a cytokine triumvirate in cancer. Front Oncol. 2019;9:969. DOI: 10.3389/fonc.2019.00969
   PubMedGoogle Scholar
• Hisada M, Kamiya S, Fujita K, et al. Potent antitumor activity of interleukin-27. Cancer Res. 2004;64(3):1152–1156. DOI: 10.1158/0008-5472.can-03-2084
   PubMed Web of Science ®Google Scholar
• Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol. 2010;2010:832454. DOI: 10.1155/2010/832454
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Wang T, Chen Y, Nie H, Huang Y, Zhao Y, Yang J. IL-27 inhibits non-small-cell lung cancer cell metastasis by miR-935 in vitro. Onco Targets Ther. 2019;12:1447–1454. DOI: 10.2147/OTT.S173207
   PubMedGoogle Scholar
• Kopiński P, Wandtke T, Dyczek A, et al. Increased levels of interleukin 27 in patients with early clinical stages of non-small cell lung cancer. Pol Arch Intern Med. 2018;128(2):105–114. DOI: 10.20452/pamw.4156
   PubMedGoogle Scholar
• Babadi AS, Kiani A, Mortaz E, et al. Serum interleukin-27 level in different clinical stages of lung cancer. Open Access Maced J Med Sci. 2019;7(1):45–49. DOI: 10.3889/oamjms.2019.018
   PubMedGoogle Scholar
• Ahmed HA, Maklad AM, Khaled SA, Elyamany A. Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers. J Blood Med. 2019;10:341–349. DOI: 10.2147/JBM.S221301
   PubMed Web of Science ®Google Scholar
• Stephens N, Ito S, Strickland SA, et al. High levels of IL-27 occur in newly diagnosed Acute Myeloid Leukemia (AML) and may influence outcome by suppressing T cell function. Blood. 2013;122(21):2567–2567. DOI: 10.1182/blood.V122.21.2567.2567
   Web of Science ®Google Scholar
• Jia H, Dilger P, Bird C, Wadhwa M. IL-27 promotes proliferation of human leukemic cell lines through the MAPK/ERK signaling pathway and suppresses sensitivity to chemotherapeutic drugs. J Interferon Cytokine Res. 2016;36(5):302–316. DOI: 10.1089/jir.2015.0091
   PubMed Web of Science ®Google Scholar
• Zorzoli A, Di Carlo E, Cocco C, et al. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Clin Cancer Res. 2012;18(6):1630–1640. DOI: 10.1158/1078-0432.CCR-11-2432
   PubMed Web of Science ®Google Scholar
• Canale S, Cocco C, Frasson C, et al. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia. 2011;25(12):1815–1824. DOI: 10.1038/leu.2011.158
   PubMed Web of Science ®Google Scholar
• Song X-N, Yang J-Z, Sun L-X, et al. Expression levels of IL-27 and IL-17 in multiple myeloma patients: a higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival. Leuk Res. 2013;37(9):1094–1099. DOI: 10.1016/j.leukres.2013.06.022
   PubMed Web of Science ®Google Scholar
• Cocco C, Giuliani N, Di Carlo E, et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res. 2010;16(16):4188–4197. DOI: 10.1158/1078-0432.CCR-10-0173
   PubMed Web of Science ®Google Scholar
• Cocco C, Di Carlo E, Zupo S, et al. Complementary IL-23 and IL-27 anti-tumor activities cause strong inhibition of human follicular and diffuse large B-cell lymphoma growth in vivo. Leukemia. 2012;26(6):1365–1374. DOI: 10.1038/leu.2011.363
   PubMed Web of Science ®Google Scholar
• Diakowska D, Lewandowski A, Markocka-Mączka K, Grabowski K. Concentration of serum interleukin-27 increase in patients with lymph node metastatic gastroesophageal cancer. Adv Clin Exp Med. 2013;22(5):683–691.
   PubMed Web of Science ®Google Scholar
• Tao Y-P, Wang W-L, Li S-Y, et al. Associations between polymorphisms in IL-12A, IL-12B, IL-12Rβ1, IL-27 gene and serum levels of IL-12p40, IL-27p28 with esophageal cancer. J Cancer Res Clin Oncol. 2012;138(11):1891–1900. DOI: 10.1007/s00432-012-1269-0
   PubMed Web of Science ®Google Scholar
• Zhu C, Zhang R, Liu L, et al. Hepatitis B virus enhances interleukin-27 expression both in vivo and in vitro. Clin Immunol. 2009;131(1):92–97. DOI: 10.1016/j.clim.2008.10.011
   PubMed Web of Science ®Google Scholar
• Rocha GA, de Melo FF, Cabral MMDA, de Brito BB, da Silva FAF, Queiroz DMM. Interleukin-27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori-associated gastroduodenal diseases. Helicobacter. 2020;25(1):e12667. DOI: 10.1111/hel.12667
   PubMed Web of Science ®Google Scholar
• Bockerstett KA, Nguyen T-LM, Wong CF, Ford EL, DiPaolo RJ. IL-27 regulates gastric metaplasia through effects on both immune and epithelial cells. Gastroenterology. 2017;152(5):S55–S56. DOI: 10.1016/s0016-5085(17)30540-1
   Web of Science ®Google Scholar
• Khodadadi A, Razmkhah M, Eskandari A-R, et al. IL-23/IL-27 ratio in peripheral blood of patients with breast cancer. Iran J Med Sci. 2014;39(4):350–356. (4):
   PubMedGoogle Scholar
• Lu D, Zhou X, Yao L, Liu C, Jin F, Wu Y. Clinical implications of the interleukin 27 serum level in breast cancer. J Investig Med. 2014;62(3):627–631. DOI: 10.2310/JIM.0000000000000046
   PubMed Web of Science ®Google Scholar
• Yan H, Viswanadhapalli S, Fernandez M, et al. Abstract P4-06-15: role of B lymphocytes and B cell-produced IL-27 in breast cancer progression and drug resistance. Cancer Res. 2019;79(4 Supplement):P4-06-15–P4-06-15. DOI: 10.1158/1538-7445.SABCS18-P4-06-15
   Google Scholar
• Yan H, Viswanadhapalli S, Perez D, et al. Taylor J. B cells produce IL-27 in breast cancer to upregulate PD-L1 expression and promote tumor progression. AACR; Apr 27–28 and Jun 22–24, 2020.
   Google Scholar
• Di Carlo E, Sorrentino C, Zorzoli A, et al. The antitumor potential of Interleukin-27 in prostate cancer. Oncotarget. 2014;5(21):10332–10341. DOI: 10.18632/oncotarget.1425
   PubMedGoogle Scholar
• Kourko O, Smyth R, Cino D, et al. Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment. J Interferon Cytokine Res. 2019;39(8):483–494. DOI: 10.1089/jir.2018.0166
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhou B, Zhang K, Song Y, Zhang L, Xi M. IL-27 suppresses SKOV3 cells proliferation by enhancing STAT3 and inhibiting the Akt signal pathway. Mol Immunol. 2016;78:155–163. DOI: 10.1016/j.molimm.2016.09.014
   PubMed Web of Science ®Google Scholar
• Petretto A, Carbotti G, Inglese E, et al. Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells. Oncotarget. 2016;7(45):72518–72536. DOI: 10.18632/oncotarget.12235
   PubMedGoogle Scholar
• Carbotti G, Barisione G, Airoldi I, et al. IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget. 2015;6(41):43267–43280. DOI: 10.18632/oncotarget.6530
   PubMedGoogle Scholar
• d'Almeida SM, Kauffenstein G, Roy C, et al. The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: regulatory role of IL-27. Oncoimmunology. 2016;5(7):e1178025. DOI: 10.1080/2162402X.2016.1178025
   PubMed Web of Science ®Google Scholar
• Rausch M, Hua J, Moodley D, et al. Abstract 4550: Increased IL-27 is associated with poor prognosis in renal cell carcinoma and supports use of SRF388, a first-in-class IL-27p28 blocking antibody, to counteract IL-27-mediated immunosuppression in this setting. Cancer Res. 2020;80(16 Supplement):4550–4550. DOI: 10.1158/1538-7445.AM2020-4550
   Web of Science ®Google Scholar
• Ghahartars M, Najafzadeh S, Abtahi S, Fattahi MJ, Ghaderi A. Investigation of Interleukin-27 in the Sera of Nonmelanoma Skin Cancer Patients. Dermatol Res Pract. 2018;2018:1–5. DOI: 10.1155/2018/8321302
   Web of Science ®Google Scholar
• Bisevac JP, Stanojevic I, Mijuskovic Z, Banovic T, Djukic M, Vojvodic D. High Interleukin 27 Production is Associated with Early Clinical Stage and Localized Disease in Patients with Melanoma. J Med Biochem. 2016;35(4):443–450. DOI: 10.1515/jomb-2016-0018
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Morishima N, Mizoguchi I, et al. Antiproliferative activity of IL-27 on melanoma. J Immunol. 2008;180(10):6527–6535. DOI: 10.4049/jimmunol.180.10.6527
   PubMed Web of Science ®Google Scholar
• Phan AT, Hunter CA. Abstract B202: Defining the role of IL-27 signaling on responses to metastatic melanoma. Cancer Immunol Res. 2019;7(2 Supplement):B202–B202. DOI: 10.1158/2326-6074.CRICIMTEATIAACR18-B202
   Web of Science ®Google Scholar
• Gonin J, Carlotti A, Dietrich C, et al. Expression of IL-27 by tumor cells in invasive cutaneous and metastatic melanomas [corrected]. PLoS One. 2013;8(10):e75694. DOI: 10.1371/journal.pone.0075694.
   PubMed Web of Science ®Google Scholar
• Ho M-Y, Leu S-JJ, Sun G-H, Tao M-H, Tang S-J, Sun K-H. IL-27 directly restrains lung tumorigenicity by suppressing Cyclooxygenase-2-Mediated activities. J Immunol. 2009;183(10):6217–6226. DOI: 10.4049/jimmunol.0901272
   PubMed Web of Science ®Google Scholar
• Lee M-H, Kachroo P, Pagano PC, et al. Combination treatment with apricoxib and IL-27 enhances inhibition of epithelial-mesenchymal transition in human lung cancer cells through a STAT1 dominant pathway. J Cancer Sci Ther. 2014;6(11):468–477. DOI: 10.4172/1948-5956.1000310
   PubMedGoogle Scholar
• Hu P, Hu H-D, Chen M, et al. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol. 2009;46(8–9):1654–1662. DOI: 10.1016/j.molimm.2009.02.025
   PubMed Web of Science ®Google Scholar
• Zhu J, Liu J-Q, Shi M, et al. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. JCI Insight. 2018;3(7):e98745. DOI: 10.1172/jci.insight.98745
   PubMed Web of Science ®Google Scholar
• Zhou W-J, Chang K-K, Wu K, et al. Rapamycin synergizes with cisplatin in antiendometrial cancer activation by improving IL-27-stimulated cytotoxicity of NK cells. Neoplasia. 2018;20(1):69–79. DOI: 10.1016/j.neo.2017.11.003
   PubMed Web of Science ®Google Scholar
• Figueiredo ML, Figueiredo Neto M, Salameh JW, et al. Ligand-mediated targeting of cytokine Interleukin-27 enhances its bioactivity in vivo. Mol Ther Methods Clin Dev. 2020;17:739–751. DOI: 10.1016/j.omtm.2020.03.022.
   PubMed Web of Science ®Google Scholar
• Fabbi M, Carbotti G, Ferrini S. Dual roles of IL-27 in cancer biology and immunotherapy. Mediators Inflamm. 2017;2017:3958069. DOI: 10.1155/2017/3958069
   PubMed Web of Science ®Google Scholar
• Zhu C, Sakuishi K, Xiao S, et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun. 2015;6(1):6072. DOI: 10.1038/ncomms7072
   PubMed Web of Science ®Google Scholar